(KMDA) Kamada Ltd. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(KMDA) Kamada Ltd. Complete Analysis Pack
Unlock Strategic Clarity
This Kamada Ltd. BCG Matrix is a company-specific strategy tool used to evaluate the portfolio’s Stars, Cash Cows, Question Marks, and Dogs, helping with investment, planning, and research decisions. What you see on this page is a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
GLASSIA, AATD plasma therapy
GLASSIA is Kamada Ltd.'s plasma-derived alpha-1 proteinase inhibitor for alpha-1 antitrypsin deficiency, a rare disease that affects about 1 in 2,500 to 1 in 5,000 people with severe deficiency. As diagnosis improves, patients often need long-term weekly augmentation therapy, which supports steady demand. That makes GLASSIA Kamada Ltd.'s clearest Star: specialist need plus a branded biologics position.
KEDRAB and KAMRAB, rabies immunoglobulin
KEDRAB and KAMRAB are rabies immunoglobulins used for post-exposure prophylaxis, a medically required step after a bite or suspected exposure. Their value comes from dependable supply, since treatment must be given fast and paired with vaccine. Kamada’s niche is defensible, and partner-led sales can widen reach in hospital and emergency channels.
VARIZIG, FDA-approved VZIG
VARIZIG is Kamada Ltd.’s varicella-zoster immune globulin for high-risk exposure, and it is the only FDA-approved VZIG in the United States. That lone U.S. approval gives Kamada pricing power and a strong niche moat, which fits Star economics even in a small market. The product serves patients who need passive protection after exposure, where demand is tied to high-risk clinical use.
Takeda plasma manufacturing partnership
Kamada's Takeda plasma manufacturing partnership can sit in the Star quadrant when utilization and shipment volumes rise, because plasma-derived biologics need tight GMP controls, long release cycles, and scarce supply. Takeda's plasma business spans a global network with more than 300 plasma collection centers, so contract demand can stay sticky.
- High regulatory moat
- Long lead times support pricing
- More volume lifts plant absorption
- Star if shipments keep rising
Kedrion collaboration supply line
Kamada’s Kedrion Biopharma partnership on plasma-derived products widens distribution beyond Kamada Ltd. branded sales and can lift share in third-party channels. If volumes keep rising and margins stay solid, this supply line fits the Star quadrant in a BCG Matrix view.
- Broader reach than own-brand sales
- Supports plasma-derived product scale
- Star case depends on volume growth
Rare-Need Stars: GLASSIA, KEDRAB/KAMRAB, and VARIZIG
GLASSIA, KEDRAB/KAMRAB, and VARIZIG fit Stars because each serves a must-treat rare or exposure-driven need, with regulatory barriers that support price and demand. GLASSIA targets alpha-1 antitrypsin deficiency, affecting about 1 in 2,500 to 1 in 5,000 severe cases, while VARIZIG is the only FDA-approved VZIG in the United States.
| Product | Star driver | Key fact |
|---|---|---|
| GLASSIA | Chronic rare-disease use | 1 in 2,500 to 1 in 5,000 |
| KEDRAB/KAMRAB | Urgent post-exposure care | Fast, paired-with-vaccine use |
| VARIZIG | U.S. niche monopoly | Only FDA-approved VZIG |
What is included in the product
Detailed Word Document
Kamada Ltd. BCG Matrix maps its portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page Kamada Ltd. BCG Matrix highlighting each business unit to simplify portfolio decisions.
Reference Sources
Kamada Ltd. Reference Sources add credibility and decision support by giving a clear, traceable trail behind key assumptions and claims.
Cash Cows
CYTOGAM, CMV immune globulin
CYTOGAM, Kamada Ltd.’s CMV immune globulin, is used to prevent cytomegalovirus disease in transplant recipients across 4 solid-organ settings, so demand is steady and protocol driven.
That maturity makes it a classic Cash Cow: low growth, specialist use, and repeat hospital ordering with limited need for major market-building spend.
In Kamada Ltd.’s mix, CYTOGAM helps generate reliable cash flow from an established, niche biologic rather than a fast-expanding growth product.
HEPAGAM B, hepatitis B immune globulin
HEPAGAM B is a mature cash cow for Kamada Ltd. It protects against hepatitis B recurrence after liver transplant and is also used for post-exposure prophylaxis, so demand stays steady instead of fast growing. The market is narrow but dependable, and recurring transplant use supports stable sales with limited promotion. That makes HEPAGAM B a low-drama cash generator in Kamada Ltd.'s portfolio.
WINRHO SDF, anti-D immune globulin
WINRHO SDF treats immune thrombocytopenic purpura and Rh isoimmunization, two long-used, clinically standardized indications. In Kamada Ltd.'s BCG Matrix, that makes it a Cash Cow: mature demand, low category growth, and steady cash generation. The U.S. anti-D immune globulin market has been stable for years, with no major new therapeutic class displacing it.
KamRho(D), Rh prophylaxis brand
Kamada Ltd.’s KamRho(D) is its Rh immunoglobulin brand in Israel, a mature prophylaxis product with steady, predictable demand. As a Cash Cow, it can keep generating cash with only modest support, since Rh-negative pregnancy prevention is routine, protocol-driven care.
- Stable, repeat-use hospital and clinic demand
- Low growth, but reliable cash flow
- Needs limited marketing support
- Fits a Cash Cow BCG profile
Vipera palaestinae and Echis coloratus antiserum
Vipera palaestinae and Echis coloratus antiserum fits the Cash Cows box: it serves a narrow, hard-to-replace need, so demand is small but sticky. Kamada reported 2025 revenue of about US$161 million, with specialty plasma products still driving the core business. In this niche, the value is steady cash, not scale.
- Small regional market
- High specialization
- Low growth, steady cash
Kamada’s Cash Cows Keep the Revenue Engine Running
Kamada Ltd.’s Cash Cows are mature plasma and immunoglobulin brands that sell in stable, protocol-led niches. CYTOGAM, HEPAGAM B, WINRHO SDF, KamRho(D), and the snake antiserum products keep generating repeat hospital and clinic demand with limited growth spend. In 2025, Kamada Ltd. reported about US$161 million in revenue, showing how these steady brands still fund the portfolio.
| Product | Role | 2025 note |
|---|---|---|
| CYTOGAM | Cash Cow | Stable transplant use |
| HEPAGAM B | Cash Cow | Recurring transplant demand |
| WINRHO SDF | Cash Cow | Long-used niche therapy |
Preview Before You Purchase
Kamada Ltd. Reference Sources
The Kamada Ltd. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content, no hidden changes—just the full, professionally formatted report ready for use. Once purchased, you’ll get immediate access to the complete version for analysis, planning, or presentation.
Dogs
BRAMITOB distribution
BRAMITOB is a third-party inhaled antibiotic in Kamada Ltd.’s distribution business, and it fits the Dog bucket because the market is mature and crowded. Inhaled tobramycin products face strong generic price pressure, so differentiation is weak and margin upside is limited. That makes BRAMITOB a low-growth, low-share asset that is more likely to consume sales effort than create value.
FOSTER distribution
FOSTER, distributed by Kamada, fits the Dog quadrant because it serves a mature, crowded asthma maintenance market where price pressure is high and brand switching is common. Global asthma affects about 262 million people, but growth is slow and competition from generic and low-cost inhaled therapies keeps share thin. With limited share in a low-growth category, FOSTER is more of a cash-preservation asset than a growth driver.
PROVOCHOLINE
PROVOCHOLINE is used to diagnose bronchial airway hyperreactivity, but the testing niche is narrow and patient volumes stay limited. In Kamada Ltd.’s BCG Matrix, that fits a Dog: low share, low growth, and modest cash upside. It serves a specific clinical need, but it is not a scale driver.
Small-volume Israeli specialty imports
Kamada’s small-volume Israeli specialty imports fit the Dogs box: they serve narrow indications, so demand stays fragmented and sales effort is high for limited scale. In 2025, Kamada reported full-year revenue of about $160 million, but these third-party lines likely add less margin than its core plasma and proprietary products.
They can still support local relationships, yet they rarely build pricing power or repeat volume. One-liner: good coverage, weak scale.
- Small indications
- Fragmented demand
- High sales effort
- Low scale leverage
Mature low-margin partner brands
Kamada Ltd.’s mature partner brands mainly support channel breadth and customer coverage, but they usually add more assortment than profit. In BCG terms, that is Dog behavior unless share improves; without verified FY2025/FY2026 brand-level margin data here, the case for holding them depends on whether they lift cross-sell or stay low-return.
- Protect reach, not returns.
- Keep only if share can rise.
- Trim if margins stay thin.
Kamada’s Dog Products: Coverage Without Much Growth
BRAMITOB, FOSTER, PROVOCHOLINE, and small Israeli imports sit in Kamada Ltd.’s Dog bucket: mature niches, weak share, and limited growth. In 2025, Kamada Ltd. reported about $160 million revenue, but these lines likely add more coverage than profit. They fit a hold-or-trim logic unless share or margins improve.
| Brand | BCG | Why |
|---|---|---|
| BRAMITOB | Dog | Generic pressure |
| FOSTER | Dog | Crowded asthma market |
| PROVOCHOLINE | Dog | Niche testing volume |
Question Marks
IVIG distribution
IVIG is in a large, growing immunology market, with global demand still expanding at about 7% to 8% a year and the market sized in the mid-teens of billions of dollars in 2025. Kamada’s role is mainly distribution, not category leadership, so it captures less pricing power and less brand pull than top suppliers. That makes IVIG distribution a Question Mark: attractive growth, but uncertain share and execution.
VARITECT
VARITECT remains a Question Mark for Kamada Ltd. because it is a specialty immunoglobulin in a prophylaxis market that is useful but crowded, so share gains are still hard to win. In 2025, the product still needs more scale, broader reach, and stronger conversion to move toward a higher-share position. If Kamada can grow volume and distribution faster in 2026, VARITECT can start to shift out of this low-share, high-potential box.
Hemophilia A and B factors
Hemophilia A and B remain active, fast-moving markets: about 1 in 5,000 male births for Hemophilia A and 1 in 25,000 for Hemophilia B, with newer non-factor and gene therapies keeping the field innovative. Kamada appears to play mainly a distribution role, not a proprietary leadership role, so its direct share is likely small versus the bigger therapy makers. The opportunity is real, but in BCG terms this fits a Question Mark because growth is there and market position is still limited.
Hereditary angioedema therapies
Hereditary angioedema is a premium specialty niche with ongoing product innovation, and Kamada Ltd. reaches it mainly through distribution. That means Kamada can benefit from a growing market while still holding a low direct share, which fits the classic Question Mark profile in the BCG Matrix.
- High growth, low share
- Distribution-led exposure
- Innovation supports demand
Japanese encephalitis and travel-medicine products
Japanese encephalitis is a niche travel-medicine "Question Mark": WHO still cites about 68,000 cases a year, mostly in Asia-Pacific, and rising travel plus vaccine awareness can lift demand. Still, the channel is local and fragmented, so Kamada is unlikely to win a large share even if the market grows.
- Growth tailwind: travel and awareness.
- Weak scale: local, fragmented distribution.
- Share likely stays limited for Kamada.
Kamada’s Question Marks: Growth Without Market Dominance
Kamada Ltd. Question Marks are high-growth, low-share bets: IVIG, VARITECT, hemophilia, hereditary angioedema, and Japanese encephalitis all sit in expanding specialty markets, but Kamada mainly distributes rather than leads. In 2025, the upside is real, yet share, scale, and pricing power stay limited.
| Product | 2025 signal | BCG |
|---|---|---|
| IVIG | 7% to 8% growth | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.